Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2025-12-25 @ 10:55 PM
Study NCT ID:
NCT05796167
Status:
WITHDRAWN
Last Update Posted:
2024-12-20
First Post:
2023-01-31
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pimavanserin for Sleep in Parkinson Disease
Sponsor:
State University of New York - Downstate Medical Center
Organization:
Study Overview
Official Title:
Does Pimavanserin (Nuplazid) Improve Sleep in Patients With Parkinson Disease Psychosis? A Pilot Study
Status:
WITHDRAWN
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The PI did not have eligible candidates. Therefore, Acadia Pharmaceuticals (the sponsor) closed the study.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g., visual hallucinations, delusions) and sleep problems.
Detailed Description:
This is a feasibility study to determine whether pimavanserin improves sleep quality in patients with PD and visual hallucinations/delusions.
Patients will complete a Screening Visit to assess eligibility to participate in the study.
For more information, please contact Sofya Glazman, a study coordinator, at sofya.glazman@downstate.edu
Patients will complete a Screening Visit to assess eligibility to participate in the study.
For more information, please contact Sofya Glazman, a study coordinator, at sofya.glazman@downstate.edu
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 1396075255 | OTHER | Acadia Pharmaceuticals Inc | View |